{"classes":[{"categories":[{"measurements":[{"comment":"Study terminated early, with immature outcome data. There was not enough follow up to determine 2-year RFS status for these subjects prior to study termination.","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Comparison of 2 year RFS in patient with detectable LSCs in the marrow at the end of consolidation to the 2 year RFS of patients without detectable LSCs. IWG Criteria (Cheson 2003) was utilized to classify relapse, with relapse defined as ≥ 5% blasts in the marrow or peripheral blood, extramedullary disease, or disease presence determined by a physician upon clinical assessment.","groups":[{"description":"Of the subjects enrolled in the evaluable cohort (either allo HCT or consolidation chemotherapy), those who had leukemia stem cells detected post-consolidation. Note, eLSC indicates the time point after consolidation.","id":"OG000","title":"eLSC+ (Evaluable Cohort)"},{"description":"Of the subjects enrolled in the evaluable cohort (either allo HCT or consolidation chemotherapy), those who had leukemia stem cells not detected post-consolidation. Note, eLSC indicates the time point after consolidation.","id":"OG001","title":"eLSC- (Evaluable Cohort)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The primary efficacy analyses will be conducted on the subset of subjects who were included in the evaluable cohort (HCT or chemo treatment arm) and who also had a successful/interpretable end of consolidation eLSC assay. This excludes subjects in OC1 and 2, as they did not achieve CR to induction or did not have the immunophenotype of interest.","reportingStatus":"POSTED","timeFrame":"2 years","title":"2 Year Relapse Free Survival (RFS)","type":"PRIMARY","unitOfMeasure":"Participants"}